| GeneLibs

题目:: [ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
作者:: Takahashi(Shunji)
状态:: 发布时间2011-08-04 , 更新时间 2015-11-19
期刊:: Clin Calcium
摘要:: Treatment for cancer may cause gonadal dysfunction and bone loss (cancer treatment-induced bone loss ; CTIBL) . Especially, endocrine therapies for breast cancer or prostate cancer carry a significant risk of CTIBL. Therapy-induced premature menopause in premenopausal breast cancer patients, aromatase inhibitor in postmenopausal breast cancer patients, and LHRH agonist with or without anti-androgen in prostate cancer patients may cause bone loss of 5% or more. RANKL (receptor activator of nuclear factor-κB ligand) antibody (denosumab) is effective for prevention of CTIBL and it may prevent CTIBL-induced fracture. During cancer treatment with gonadal dysfunction, bone mineral density should be carefully followed to avoid QOL impairment due to osoteoporosis.
语言:: jpn
DOI:: CliCa110812391247

文献库文献相关信息